Hereditary Angioedema Drug-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Hereditary Angioedema Drug-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Hereditary Angioedema Drug industry, standing on the readers? perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Hereditary Angioedema Drug 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Hereditary Angioedema Drug worldwide and market share by regions, with company and product introduction, position in the Hereditary Angioedema Drug market
Market status and development trend of Hereditary Angioedema Drug by types and applications
Cost and profit status of Hereditary Angioedema Drug, and marketing status
Market growth drivers and challenges
The report segments the global Hereditary Angioedema Drug market as:
Global Hereditary Angioedema Drug Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Hereditary Angioedema Drug Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
By Product
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Route of Administration
Oral
Intravenous
Subcutaneous Injection
Global Hereditary Angioedema Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Global Hereditary Angioedema Drug Market: Manufacturers Segment Analysis (Company and Product introduction, Hereditary Angioedema Drug Sales Volume, Revenue, Price and Gross Margin):
Pharming Group NV
Shire plc
CSL Limited
iBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Hereditary Angioedema Drug-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Hereditary Angioedema Drug industry, standing on the readers? perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Hereditary Angioedema Drug 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Hereditary Angioedema Drug worldwide and market share by regions, with company and product introduction, position in the Hereditary Angioedema Drug market
Market status and development trend of Hereditary Angioedema Drug by types and applications
Cost and profit status of Hereditary Angioedema Drug, and marketing status
Market growth drivers and challenges
The report segments the global Hereditary Angioedema Drug market as:
Global Hereditary Angioedema Drug Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Hereditary Angioedema Drug Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
By Product
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Route of Administration
Oral
Intravenous
Subcutaneous Injection
Global Hereditary Angioedema Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Global Hereditary Angioedema Drug Market: Manufacturers Segment Analysis (Company and Product introduction, Hereditary Angioedema Drug Sales Volume, Revenue, Price and Gross Margin):
Pharming Group NV
Shire plc
CSL Limited
iBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF HEREDITARY ANGIOEDEMA DRUG
1.1 Definition of Hereditary Angioedema Drug in This Report
1.2 Commercial Types of Hereditary Angioedema Drug
1.2.1 By Product
1.2.2 C1 Esterase Inhibitor
1.2.3 Kallikrein Inhibitor
1.2.4 Selective Bradykinin B2 Receptor Antagonist
1.2.5 By Route of Administration
1.2.6 Oral
1.2.7 Intravenous
1.2.8 Subcutaneous Injection
1.3 Downstream Application of Hereditary Angioedema Drug
1.3.1 Retail Pharmacies
1.3.2 Hospital Pharmacies
1.3.3 Online Pharmacies
1.4 Development History of Hereditary Angioedema Drug
1.5 Market Status and Trend of Hereditary Angioedema Drug 2013-2023
1.5.1 Global Hereditary Angioedema Drug Market Status and Trend 2013-2023
1.5.2 Regional Hereditary Angioedema Drug Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Hereditary Angioedema Drug 2013-2017
2.2 Sales Market of Hereditary Angioedema Drug by Regions
2.2.1 Sales Volume of Hereditary Angioedema Drug by Regions
2.2.2 Sales Value of Hereditary Angioedema Drug by Regions
2.3 Production Market of Hereditary Angioedema Drug by Regions
2.4 Global Market Forecast of Hereditary Angioedema Drug 2018-2023
2.4.1 Global Market Forecast of Hereditary Angioedema Drug 2018-2023
2.4.2 Market Forecast of Hereditary Angioedema Drug by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Hereditary Angioedema Drug by Types
3.2 Sales Value of Hereditary Angioedema Drug by Types
3.3 Market Forecast of Hereditary Angioedema Drug by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Hereditary Angioedema Drug by Downstream Industry
4.2 Global Market Forecast of Hereditary Angioedema Drug by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Hereditary Angioedema Drug Market Status by Countries
5.1.1 North America Hereditary Angioedema Drug Sales by Countries (2013-2017)
5.1.2 North America Hereditary Angioedema Drug Revenue by Countries (2013-2017)
5.1.3 United States Hereditary Angioedema Drug Market Status (2013-2017)
5.1.4 Canada Hereditary Angioedema Drug Market Status (2013-2017)
5.1.5 Mexico Hereditary Angioedema Drug Market Status (2013-2017)
5.2 North America Hereditary Angioedema Drug Market Status by Manufacturers
5.3 North America Hereditary Angioedema Drug Market Status by Type (2013-2017)
5.3.1 North America Hereditary Angioedema Drug Sales by Type (2013-2017)
5.3.2 North America Hereditary Angioedema Drug Revenue by Type (2013-2017)
5.4 North America Hereditary Angioedema Drug Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Hereditary Angioedema Drug Market Status by Countries
6.1.1 Europe Hereditary Angioedema Drug Sales by Countries (2013-2017)
6.1.2 Europe Hereditary Angioedema Drug Revenue by Countries (2013-2017)
6.1.3 Germany Hereditary Angioedema Drug Market Status (2013-2017)
6.1.4 UK Hereditary Angioedema Drug Market Status (2013-2017)
6.1.5 France Hereditary Angioedema Drug Market Status (2013-2017)
6.1.6 Italy Hereditary Angioedema Drug Market Status (2013-2017)
6.1.7 Russia Hereditary Angioedema Drug Market Status (2013-2017)
6.1.8 Spain Hereditary Angioedema Drug Market Status (2013-2017)
6.1.9 Benelux Hereditary Angioedema Drug Market Status (2013-2017)
6.2 Europe Hereditary Angioedema Drug Market Status by Manufacturers
6.3 Europe Hereditary Angioedema Drug Market Status by Type (2013-2017)
6.3.1 Europe Hereditary Angioedema Drug Sales by Type (2013-2017)
6.3.2 Europe Hereditary Angioedema Drug Revenue by Type (2013-2017)
6.4 Europe Hereditary Angioedema Drug Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Hereditary Angioedema Drug Market Status by Countries
7.1.1 Asia Pacific Hereditary Angioedema Drug Sales by Countries (2013-2017)
7.1.2 Asia Pacific Hereditary Angioedema Drug Revenue by Countries (2013-2017)
7.1.3 China Hereditary Angioedema Drug Market Status (2013-2017)
7.1.4 Japan Hereditary Angioedema Drug Market Status (2013-2017)
7.1.5 India Hereditary Angioedema Drug Market Status (2013-2017)
7.1.6 Southeast Asia Hereditary Angioedema Drug Market Status (2013-2017)
7.1.7 Australia Hereditary Angioedema Drug Market Status (2013-2017)
7.2 Asia Pacific Hereditary Angioedema Drug Market Status by Manufacturers
7.3 Asia Pacific Hereditary Angioedema Drug Market Status by Type (2013-2017)
7.3.1 Asia Pacific Hereditary Angioedema Drug Sales by Type (2013-2017)
7.3.2 Asia Pacific Hereditary Angioedema Drug Revenue by Type (2013-2017)
7.4 Asia Pacific Hereditary Angioedema Drug Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Hereditary Angioedema Drug Market Status by Countries
8.1.1 Latin America Hereditary Angioedema Drug Sales by Countries (2013-2017)
8.1.2 Latin America Hereditary Angioedema Drug Revenue by Countries (2013-2017)
8.1.3 Brazil Hereditary Angioedema Drug Market Status (2013-2017)
8.1.4 Argentina Hereditary Angioedema Drug Market Status (2013-2017)
8.1.5 Colombia Hereditary Angioedema Drug Market Status (2013-2017)
8.2 Latin America Hereditary Angioedema Drug Market Status by Manufacturers
8.3 Latin America Hereditary Angioedema Drug Market Status by Type (2013-2017)
8.3.1 Latin America Hereditary Angioedema Drug Sales by Type (2013-2017)
8.3.2 Latin America Hereditary Angioedema Drug Revenue by Type (2013-2017)
8.4 Latin America Hereditary Angioedema Drug Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Hereditary Angioedema Drug Market Status by Countries
9.1.1 Middle East and Africa Hereditary Angioedema Drug Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Hereditary Angioedema Drug Revenue by Countries (2013-2017)
9.1.3 Middle East Hereditary Angioedema Drug Market Status (2013-2017)
9.1.4 Africa Hereditary Angioedema Drug Market Status (2013-2017)
9.2 Middle East and Africa Hereditary Angioedema Drug Market Status by Manufacturers
9.3 Middle East and Africa Hereditary Angioedema Drug Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Hereditary Angioedema Drug Sales by Type (2013-2017)
9.3.2 Middle East and Africa Hereditary Angioedema Drug Revenue by Type (2013-2017)
9.4 Middle East and Africa Hereditary Angioedema Drug Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF HEREDITARY ANGIOEDEMA DRUG
10.1 Global Economy Situation and Trend Overview
10.2 Hereditary Angioedema Drug Downstream Industry Situation and Trend Overview
CHAPTER 11 HEREDITARY ANGIOEDEMA DRUG MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Hereditary Angioedema Drug by Major Manufacturers
11.2 Production Value of Hereditary Angioedema Drug by Major Manufacturers
11.3 Basic Information of Hereditary Angioedema Drug by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Hereditary Angioedema Drug Major Manufacturer
11.3.2 Employees and Revenue Level of Hereditary Angioedema Drug Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 HEREDITARY ANGIOEDEMA DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Pharming Group NV
12.1.1 Company profile
12.1.2 Representative Hereditary Angioedema Drug Product
12.1.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of Pharming Group NV
12.2 Shire plc
12.2.1 Company profile
12.2.2 Representative Hereditary Angioedema Drug Product
12.2.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of Shire plc
12.3 CSL Limited
12.3.1 Company profile
12.3.2 Representative Hereditary Angioedema Drug Product
12.3.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of CSL Limited
12.4 iBio Inc.
12.4.1 Company profile
12.4.2 Representative Hereditary Angioedema Drug Product
12.4.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of iBio Inc.
12.5 BioCryst Pharmaceuticals, Inc.
12.5.1 Company profile
12.5.2 Representative Hereditary Angioedema Drug Product
12.5.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of BioCryst Pharmaceuticals, Inc.
12.6 Ionis Pharmaceuticals, Inc.
12.6.1 Company profile
12.6.2 Representative Hereditary Angioedema Drug Product
12.6.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of Ionis Pharmaceuticals, Inc.
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HEREDITARY ANGIOEDEMA DRUG
13.1 Industry Chain of Hereditary Angioedema Drug
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF HEREDITARY ANGIOEDEMA DRUG
14.1 Cost Structure Analysis of Hereditary Angioedema Drug
14.2 Raw Materials Cost Analysis of Hereditary Angioedema Drug
14.3 Labor Cost Analysis of Hereditary Angioedema Drug
14.4 Manufacturing Expenses Analysis of Hereditary Angioedema Drug
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Hereditary Angioedema Drug in This Report
1.2 Commercial Types of Hereditary Angioedema Drug
1.2.1 By Product
1.2.2 C1 Esterase Inhibitor
1.2.3 Kallikrein Inhibitor
1.2.4 Selective Bradykinin B2 Receptor Antagonist
1.2.5 By Route of Administration
1.2.6 Oral
1.2.7 Intravenous
1.2.8 Subcutaneous Injection
1.3 Downstream Application of Hereditary Angioedema Drug
1.3.1 Retail Pharmacies
1.3.2 Hospital Pharmacies
1.3.3 Online Pharmacies
1.4 Development History of Hereditary Angioedema Drug
1.5 Market Status and Trend of Hereditary Angioedema Drug 2013-2023
1.5.1 Global Hereditary Angioedema Drug Market Status and Trend 2013-2023
1.5.2 Regional Hereditary Angioedema Drug Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Hereditary Angioedema Drug 2013-2017
2.2 Sales Market of Hereditary Angioedema Drug by Regions
2.2.1 Sales Volume of Hereditary Angioedema Drug by Regions
2.2.2 Sales Value of Hereditary Angioedema Drug by Regions
2.3 Production Market of Hereditary Angioedema Drug by Regions
2.4 Global Market Forecast of Hereditary Angioedema Drug 2018-2023
2.4.1 Global Market Forecast of Hereditary Angioedema Drug 2018-2023
2.4.2 Market Forecast of Hereditary Angioedema Drug by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Hereditary Angioedema Drug by Types
3.2 Sales Value of Hereditary Angioedema Drug by Types
3.3 Market Forecast of Hereditary Angioedema Drug by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Hereditary Angioedema Drug by Downstream Industry
4.2 Global Market Forecast of Hereditary Angioedema Drug by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Hereditary Angioedema Drug Market Status by Countries
5.1.1 North America Hereditary Angioedema Drug Sales by Countries (2013-2017)
5.1.2 North America Hereditary Angioedema Drug Revenue by Countries (2013-2017)
5.1.3 United States Hereditary Angioedema Drug Market Status (2013-2017)
5.1.4 Canada Hereditary Angioedema Drug Market Status (2013-2017)
5.1.5 Mexico Hereditary Angioedema Drug Market Status (2013-2017)
5.2 North America Hereditary Angioedema Drug Market Status by Manufacturers
5.3 North America Hereditary Angioedema Drug Market Status by Type (2013-2017)
5.3.1 North America Hereditary Angioedema Drug Sales by Type (2013-2017)
5.3.2 North America Hereditary Angioedema Drug Revenue by Type (2013-2017)
5.4 North America Hereditary Angioedema Drug Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Hereditary Angioedema Drug Market Status by Countries
6.1.1 Europe Hereditary Angioedema Drug Sales by Countries (2013-2017)
6.1.2 Europe Hereditary Angioedema Drug Revenue by Countries (2013-2017)
6.1.3 Germany Hereditary Angioedema Drug Market Status (2013-2017)
6.1.4 UK Hereditary Angioedema Drug Market Status (2013-2017)
6.1.5 France Hereditary Angioedema Drug Market Status (2013-2017)
6.1.6 Italy Hereditary Angioedema Drug Market Status (2013-2017)
6.1.7 Russia Hereditary Angioedema Drug Market Status (2013-2017)
6.1.8 Spain Hereditary Angioedema Drug Market Status (2013-2017)
6.1.9 Benelux Hereditary Angioedema Drug Market Status (2013-2017)
6.2 Europe Hereditary Angioedema Drug Market Status by Manufacturers
6.3 Europe Hereditary Angioedema Drug Market Status by Type (2013-2017)
6.3.1 Europe Hereditary Angioedema Drug Sales by Type (2013-2017)
6.3.2 Europe Hereditary Angioedema Drug Revenue by Type (2013-2017)
6.4 Europe Hereditary Angioedema Drug Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Hereditary Angioedema Drug Market Status by Countries
7.1.1 Asia Pacific Hereditary Angioedema Drug Sales by Countries (2013-2017)
7.1.2 Asia Pacific Hereditary Angioedema Drug Revenue by Countries (2013-2017)
7.1.3 China Hereditary Angioedema Drug Market Status (2013-2017)
7.1.4 Japan Hereditary Angioedema Drug Market Status (2013-2017)
7.1.5 India Hereditary Angioedema Drug Market Status (2013-2017)
7.1.6 Southeast Asia Hereditary Angioedema Drug Market Status (2013-2017)
7.1.7 Australia Hereditary Angioedema Drug Market Status (2013-2017)
7.2 Asia Pacific Hereditary Angioedema Drug Market Status by Manufacturers
7.3 Asia Pacific Hereditary Angioedema Drug Market Status by Type (2013-2017)
7.3.1 Asia Pacific Hereditary Angioedema Drug Sales by Type (2013-2017)
7.3.2 Asia Pacific Hereditary Angioedema Drug Revenue by Type (2013-2017)
7.4 Asia Pacific Hereditary Angioedema Drug Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Hereditary Angioedema Drug Market Status by Countries
8.1.1 Latin America Hereditary Angioedema Drug Sales by Countries (2013-2017)
8.1.2 Latin America Hereditary Angioedema Drug Revenue by Countries (2013-2017)
8.1.3 Brazil Hereditary Angioedema Drug Market Status (2013-2017)
8.1.4 Argentina Hereditary Angioedema Drug Market Status (2013-2017)
8.1.5 Colombia Hereditary Angioedema Drug Market Status (2013-2017)
8.2 Latin America Hereditary Angioedema Drug Market Status by Manufacturers
8.3 Latin America Hereditary Angioedema Drug Market Status by Type (2013-2017)
8.3.1 Latin America Hereditary Angioedema Drug Sales by Type (2013-2017)
8.3.2 Latin America Hereditary Angioedema Drug Revenue by Type (2013-2017)
8.4 Latin America Hereditary Angioedema Drug Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Hereditary Angioedema Drug Market Status by Countries
9.1.1 Middle East and Africa Hereditary Angioedema Drug Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Hereditary Angioedema Drug Revenue by Countries (2013-2017)
9.1.3 Middle East Hereditary Angioedema Drug Market Status (2013-2017)
9.1.4 Africa Hereditary Angioedema Drug Market Status (2013-2017)
9.2 Middle East and Africa Hereditary Angioedema Drug Market Status by Manufacturers
9.3 Middle East and Africa Hereditary Angioedema Drug Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Hereditary Angioedema Drug Sales by Type (2013-2017)
9.3.2 Middle East and Africa Hereditary Angioedema Drug Revenue by Type (2013-2017)
9.4 Middle East and Africa Hereditary Angioedema Drug Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF HEREDITARY ANGIOEDEMA DRUG
10.1 Global Economy Situation and Trend Overview
10.2 Hereditary Angioedema Drug Downstream Industry Situation and Trend Overview
CHAPTER 11 HEREDITARY ANGIOEDEMA DRUG MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Hereditary Angioedema Drug by Major Manufacturers
11.2 Production Value of Hereditary Angioedema Drug by Major Manufacturers
11.3 Basic Information of Hereditary Angioedema Drug by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Hereditary Angioedema Drug Major Manufacturer
11.3.2 Employees and Revenue Level of Hereditary Angioedema Drug Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 HEREDITARY ANGIOEDEMA DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Pharming Group NV
12.1.1 Company profile
12.1.2 Representative Hereditary Angioedema Drug Product
12.1.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of Pharming Group NV
12.2 Shire plc
12.2.1 Company profile
12.2.2 Representative Hereditary Angioedema Drug Product
12.2.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of Shire plc
12.3 CSL Limited
12.3.1 Company profile
12.3.2 Representative Hereditary Angioedema Drug Product
12.3.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of CSL Limited
12.4 iBio Inc.
12.4.1 Company profile
12.4.2 Representative Hereditary Angioedema Drug Product
12.4.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of iBio Inc.
12.5 BioCryst Pharmaceuticals, Inc.
12.5.1 Company profile
12.5.2 Representative Hereditary Angioedema Drug Product
12.5.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of BioCryst Pharmaceuticals, Inc.
12.6 Ionis Pharmaceuticals, Inc.
12.6.1 Company profile
12.6.2 Representative Hereditary Angioedema Drug Product
12.6.3 Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of Ionis Pharmaceuticals, Inc.
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HEREDITARY ANGIOEDEMA DRUG
13.1 Industry Chain of Hereditary Angioedema Drug
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF HEREDITARY ANGIOEDEMA DRUG
14.1 Cost Structure Analysis of Hereditary Angioedema Drug
14.2 Raw Materials Cost Analysis of Hereditary Angioedema Drug
14.3 Labor Cost Analysis of Hereditary Angioedema Drug
14.4 Manufacturing Expenses Analysis of Hereditary Angioedema Drug
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
